scispace - formally typeset
Open AccessJournal ArticleDOI

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson’s disease

Reads0
Chats0
TLDR
This is the first study indicating that the SLC6A3/DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease, and this effect is stronger for conditions that engage the striatum.
Abstract
Parkinson’s disease is a neurodegenerative condition that affects motor function along with a wide range of cognitive domains, including executive function. The hallmark of the pathology is its significant loss of nigrostriatal dopamine, which is necessary for the cortico-striatal interactions that underlie executive control. Striatal dopamine reuptake is mediated by the SLC6A3 gene (formerly named DAT1) and its polymorphisms, which have been largely overlooked in Parkinson’s disease. Thirty patients (ages 53–68 years; 19 males, 11 females) at early stages of Parkinson’s disease, were genotyped according to a 9-repeat (9R) or 10-repeat (10R) allele on the SLC6A3/DAT1 gene. They underwent neuropsychological assessment and functional magnetic resonance imaging while performing a set-shifting task (a computerized Wisconsin Card Sorting Task) that relies on fronto-striatal interactions. Patients homozygous on the 10R allele performed significantly better on working memory tasks than 9R-carrier patients. Most importantly, patients carrying a 9R allele exhibited less activation than their 10R homozygous counterparts in the prefrontal cortex, premotor cortex and caudate nucleus, when planning and executing a set-shift. This pattern was exacerbated for conditions that usually recruit the striatum compared to those that do not. This is the first study indicating that the SLC6A3/DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson’s disease. This effect is stronger for conditions that engage the striatum. Longitudinal studies are warranted to assess this polymorphism’s effect on the clinical evolution of patients with Parkinson’s disease, especially with cognitive decline.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Meta-Analysis of Parkinson's Disease and Alzheimer's Disease Revealed Commonly Impaired Pathways and Dysregulation of NRF2-Dependent Genes.

TL;DR: A meta-analysis with 9 microarray datasets of PD and AD studies found that MAFF was upregulated in all tissues and significantly negatively correlated with the 31 NRF2-dependent genes in diseased conditions, suggesting it might play an important role in dysfunction ofNRF2 regulatory network in PD.
Journal ArticleDOI

The Role of the SLC Transporters Protein in the Neurodegenerative Disorders.

TL;DR: The role of solute carrier transporters in neurodegenerative disorders such as Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease, Parkinson’s diseases, depression, post-traumatic stress disorder, dementia, schizophrenia, and Epilepsy is reviewed and discussed to see how defects or absences in SLC transporter cause neurodegenersative disorders.
Journal ArticleDOI

Markers of cognitive decline in PD: The case for heterogeneity

TL;DR: It is proposed that the current studies looking at different types of biomarkers provide support for different causes being associated with cognitive decline in PD, and large-scale multi-disciplinary and multi-modal longitudinal studies are required to identify the different phenotypes associated with different cognitive profiles and evolution in PD.
Journal ArticleDOI

Genetic Variation and Neuroplasticity: Role in Rehabilitation After Stroke.

TL;DR: Genetic polymorphisms for brain-derived neurotrophic factor, dopamine, and apolipoprotein E have been shown to impact neuroplasticity and motor learning and should be considered as possible predictors or covariates in studies that investigate neuroPlasticity, motor learning, or motor recovery after stroke.
References
More filters
Journal ArticleDOI

The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment

TL;DR: A 10‐minute cognitive screening tool (Montreal Cognitive Assessment, MoCA) to assist first‐line physicians in detection of mild cognitive impairment (MCI), a clinical state that often progresses to dementia.
Journal ArticleDOI

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

TL;DR: The pathological findings in 100 patients diagnosed prospectively by a group of consultant neurologists as having idiopathic Parkinson's disease are reported, and these observations call into question current concepts of Parkinson's Disease as a single distinct morbid entity.
Book

Boston Naming Test

TL;DR: A process for isolating a thromboplastic material from human placentae by solvent extraction techniques and it is obtained that is useful as a blood coagulant is obtained.
Journal ArticleDOI

An economic method for the fluorescent labeling of PCR fragments

TL;DR: A poor man's approach to genotyping for research and high-throughput diagnostics and how it can be applied to medicine and science.
Journal ArticleDOI

Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space

TL;DR: A fully automatic registration method to map volumetric data into stereotaxic space that yields results comparable with those of manually based techniques and therefore does not suffer the drawbacks involved in user intervention.
Related Papers (5)